Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NFKB1 | P19838 | 1/20 | 0.58 |
| ▸ | MAOB | P27338 | 9/20 | 0.53 |
| ▸ | P4HB | P07237 | 1/20 | 0.47 |
| ▸ | ABCG2 | Q9UNQ0 | 1/20 | 0.47 |
| ▸ | GRIN2D | O15399 | 2/20 | 0.45 |
| ▸ | GRIN3B | O60391 | 2/20 | 0.45 |
| ▸ | GRIN1 | Q05586 | 2/20 | 0.45 |
| ▸ | GRIN2A | Q12879 | 2/20 | 0.45 |
| ▸ | GRIN2B | Q13224 | 2/20 | 0.45 |
| ▸ | GRIN2C | Q14957 | 2/20 | 0.45 |
| ▸ | GRIN3A | Q8TCU5 | 2/20 | 0.45 |
| ▸ | MAOA | P21397 | 1/20 | 0.44 |
| ▸ | BACE1 | P56817 | 1/20 | 0.44 |
| ▸ | TNF | P01375 | 2/20 | 0.44 |
| ▸ | IL6 | P05231 | 1/20 | 0.44 |
| ▸ | RAB9A | P51151 | 1/20 | 0.43 |
| ▸ | NOD1 | Q9Y239 | 1/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | LMNA | P02545 | 1/20 | 0.43 |
| ▸ | MAPT | P10636 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4281994 | 1.00 | NFKB1 (0.58) | NFKB1MAOBP4HBABCG2GRIN2D | |
| SCHEMBL4728560 | 0.81 | NFKB1 (0.53) | NFKB1MAOBP4HBABCG2GRIN2D | |
| SCHEMBL5644762 | 0.81 | NFKB1 (0.53) | NFKB1MAOBP4HBABCG2GRIN2D | |
| SCHEMBL7182887 | 0.81 | TDP1 (0.38) | NFKB1MAOBP4HBABCG2MEN1 | |
| SCHEMBL7182890 | 0.81 | TDP1 (0.38) | NFKB1MAOBP4HBABCG2MEN1 | |
| SCHEMBL3811810 | 0.79 | LMNA (0.41) | NFKB1MEN1LMNAMAPTKMT2A | |
| SCHEMBL7141617 | 0.75 | NFKB1 (0.60) | NFKB1MAOBP4HBABCG2GRIN2D | |
| SCHEMBL7141613 | 0.75 | NFKB1 (0.60) | NFKB1MAOBP4HBABCG2GRIN2D | |
| SCHEMBL30584115 | 0.74 | NFKB1 (0.59) | NFKB1MAOBP4HBABCG2GRIN2D | |
| SCHEMBL1403287 | 0.74 | NFKB1 (0.59) | NFKB1MAOBP4HBABCG2GRIN2D |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 46 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8012975-B2 | These compounds lack a 1,4-bridging group as found in the ecteinascidins; and, have at the C-1 position a substituent selected from an amino or hydroxy group, optionally protected or derivatized; anticarcinogenic agents | PHARMA MAR, S.A. (ES) | 2011-09-06 | — | — | US | claimed |
| US-7410969-B2 | Antitumoral analogs of ET-743 | PHARMA MAR, S.A. (ES) | 2008-08-12 | — | — | US | claimed |
| US-20080051407-A1 | These compounds lack a 1,4-bridging group as found in the ecteinascidins; and, have at the C-1 position a substituent selected from an amino or hydroxy group, optionally protected or derivatized; anticarcinogenic agents | PHARMA MAR, S.A., A MADRID SPAIN CORPORATION | 2008-02-28 | — | — | US | claimed |
| EP-1496060-B1 | Antitumoral analogs of ET-743 | PHARMA MAR SA (ES) | 2007-08-01 | — | — | EP | claimed |
| US-7247629-B2 | Antitumoral analogs of et-743 | PHARMA MAR, S.A. | 2007-07-24 | — | — | US | claimed |
| US-20060019960-A1 | Antitumoral analogs of ET-743 | PHARMA MAR, S.A. (ES) | 2006-01-26 | — | — | US | claimed |
| EP-1289999-B1 | ANTITUMORAL ANALOGS OF ET-743 | PHARMA MAR SA (ES) | 2004-11-17 | — | — | EP | claimed |
| US-6388081-B1 | 4-substituted-quinoline derivatives and 4-substituted-quinoline combinatorial libraries | LION BIOSCIENCE AG (DE) | 2002-05-14 | — | — | US | claimed |
| US-6262269-B1 | 4-Substituted-quinoline derivatives and 4-substituted-quinoline combinatorial libraries | TREGA BIOSCIENCES, INC. | 2001-07-17 | — | — | US | claimed |
| EP-0977989-A1 | 4-SUBSTITUTED-QUINOLINE DERIVATIVES AND 4-SUBSTITUTE-QUINOLINE COMBINATORIAL LIBRARIES | TREGA BIOSCIENCES, INC. (US) | 2000-02-09 | — | — | EP | claimed |
| WO-1998034115-A1 | 4-SUBSTITUTED-QUINOLINE DERIVATIVES AND 4-SUBSTITUTE-QUINOLINE COMBINATORIAL LIBRARIES | TREGA BIOSCIENCES, INC. (US) | 1998-08-06 | — | — | WO | claimed |
| EP-2257297-B1 | COMPOUNDS FOR USE IN THE TREATMENT OF ACNE, SEBORRHOEA AND SEBHORROEIC DERMATITIS, OR FOR REDUCING SEBUM SECRETION | MIMETICA PTY LTD (AU) | 2017-10-18 | — | — | EP | disclosed |
| US-20140163078-A1 | Mycobacterial Disease Detection, Treatment, and Drug Discovery | THE UAB RESEARCH FOUNDATION (US) | 2014-06-12 | — | — | US | disclosed |
| US-8603751-B2 | Mycobacterial disease detection, treatment, and drug discovery | THE UAB RESEARCH FOUNDATION (US) | 2013-12-10 | — | — | US | disclosed |
| EP-2257534-B1 | 3-AMINOALKYL-1,4-DIAZEPAN-2-ONE MELANOCORTIN-5 RECEPTOR ANTAGONISTS | MIMETICA PTY LTD (AU) | 2013-11-06 | — | — | EP | disclosed |
| EP-0977989-A1 | 4-SUBSTITUTED-QUINOLINE DERIVATIVES AND 4-SUBSTITUTE-QUINOLINE COMBINATORIAL LIBRARIES | TREGA BIOSCIENCES, INC. (US) | 2000-02-09 | — | — | EP | disclosed |
| US-5925527-A | SCREENING NEW PHARMACEUTICALS | TREGA BIOSCIENCES, INC. (US) | 1999-07-20 | — | — | US | disclosed |
| WO-1998034115-A1 | 4-SUBSTITUTED-QUINOLINE DERIVATIVES AND 4-SUBSTITUTE-QUINOLINE COMBINATORIAL LIBRARIES | TREGA BIOSCIENCES, INC. (US) | 1998-08-06 | — | — | WO | disclosed |
| EP-0795547-A1 | (Aminoalkyl- and acylaminoalkyl-oxy)benzyloxyquinolines, process for their preparation and use as Bradykinin receptor antagonists | HOECHST AKTIENGESELLSCHAFT (DE) | 1997-09-17 | — | — | EP | disclosed |
| US-4401827-A | CARDIOTONIC AND ANTILIPEMIC AGENTS; BLOOD DISORDERS | SIGMA-TAU (IT) | 1983-08-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140163078-A1 | Mycobacterial Disease Detection, Treatment, and Drug Discovery | ANP32B, ANP32A, MRPL21 | NFKB1 2786/4885MAOB 4366/4885P4HB 374/4885 |
| US-20080051407-A1 | These compounds lack a 1,4-bridging group as found in the ecteinascidins; and, have at the C-1 position a substituent selected from an amino or hydroxy group, optionally protected or derivatized; anticarcinogenic agents | FN1, RCN1, ERCC4 | NFKB1 1780/4885MAOB 790/4885P4HB 1132/4885 |
| US-20060019960-A1 | Antitumoral analogs of ET-743 | ETV1, ETV6, ETF1 | NFKB1 1313/4885MAOB 846/4885P4HB 2014/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.